NeuroVive publishes prospectus in connection with preferential rights issue
Lund, Sweden, 22 January 2019 – NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the prospectus in connection with NeuroVive Pharmaceutical AB’s (publ) (“NeuroVive” or the “Company”) previously announced preferential rights issue (“Rights Issue”) and the admission to trading of the shares in the Company on Nasdaq Stockholm has been approved and registered by the Swedish Financial Supervisory Authority as of 22 January 2019. The prospectus, application forms and other relevant information are available at the Company’s office and can be downloaded